Cruz Cobalt Corp.

Cruz Cobalt Corp. se concentre sur l'acquisition et le développement de projets Cobalt de haute qualité dans des juridictions minières politiquement stables, respectueuses de l'environnement et éthiques, essentielles pour la croissance rapide des batteries rechargeables et des secteurs de l'énergie renouvelable.

French

XPhyto Therapeutics Corp.

XPhyto est une entreprise de cannabis axée sur la science qui développe des capacités d'analyse en matière de tests, de transformation et de formulation au Canada et de recherche, de culture, d'extraction, d'importation, de distribution et de fabrication en Allemagne.

French

XPhyto Therapeutics Corp.

XPhyto is a science-based cannabis company focused on formulation, clinical validation, and emerging European markets. XPhyto’s 100% owned German subsidiary, Bunker Pflanzenextrakte GmbH, has been granted a unique German cannabis cultivation and extraction licence for scientific purposes by the German Federal Institute for Drugs and Medical Devices (BfArM). XPhyto is pursuing additional opportunities in Germany including cultivation, processing, manufacturing, import, and distribution.

English

Cruz Cobalt Corp.

Cruz Cobalt Corp is focused on acquiring and developing high-grade Cobalt projects in politically stable, environmentally responsible and ethical mining jurisdictions, essential for the rapidly growing rechargeable battery and renewable energy sectors.

English

Revive Therapeutics Ltd.

Revive Therapeutics Ltd. is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations.  Currently, the Company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza strains including COVID-19.

French

Revive Therapeutics Ltd.

Revive Therapeutics Ltd. is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations.  Currently, the Company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza strains including COVID-19.

English